CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 50 target
Drug / intervention
MR-linacdevice
Likely dose
Not stated in record
Key inclusion· 8
  • ✓Age 18 years or older
  • ✓Histologically confirmed prostate cancer
  • ✓Localized disease: low-risk (cT1-T2a, PSA <10ng/mL, Gleason ≤6) declining surveillance, intermediate-risk, or selected high-risk (cT2b-T3a/minimally T3b, PSA 10-40ng/mL, Gleason 7-8)
  • ✓Oligometastatic disease with prostate in-situ, all metastatic foci amenable to radical SBRT
Key exclusion· 5
  • ✕Contraindications to MRI
  • ✕TURP within past 6 months
  • ✕Ulcerative colitis, Crohn's disease, ataxia telangiectasia, or systemic lupus erythematosus
  • ✕Prior pelvic irradiation

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05183074
NCT05183074N/ARecruitingOn TrackUpdated 6mo ago
Long Recruiting
CompareCT.gov

Phase II Prospective Trial of MR-linac Based Stereotactic Ablative Radiotherapy for Patients With Localized (SAMRT-P01) and Oligo-metastatic (SMART-P02) Prostate Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences·interventional·Posted Jan 10, 2022·Updated Dec 11, 2025

In Brief

A clinical study evaluating MR-linac for Prostate Cancer and 6 related conditions. Currently recruiting, targeting 50 participants across 1 site.

Detailed Summary

1. To investigate the tolerability of MR-linac based stereotactic ablative radiotherapy (MRL-SBRT)for patients with localized prostate cancer 2. To assess the acute and late toxicities, efficacy and quality of life for patients treated by MRL-SBRT 3. To simulate the dose planning and assess the feasibility of simultaneous-boost for MR-prominent foci 4. To investigate the relationship between the changes of blood and tissue biomarkers and manifestations on mp-MRI pre-/post-MRL-SBRT, to further ascertain the predictive factors of local persisting and/or relapse disease

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer, Radiotherapy Side Effect, Magnetic Resonance-linac, Stereotactic Ablative RT, Adaptive Radiotherapy, Localised Disease, Oligometastatic Disease
CountriesChina
Collaborators--

Timeline

N/ARecruiting
20212022202320242025202620272028
First PostedJan 10, 2022
Enrollment StartFeb 1, 2021
Primary CompletionDec 31, 2027
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 4.5 years agoPrimary completion in 1.5 years

Interventions

MR-linacdevice

1.5-Tesla MR-linac based SBRT